Survival and hospitalization among patients with acute myeloid leukemia treated with azacitidine or decitabine in a large managed care population: A real-world, retrospective, claims-based, comparative analysis

B. D. Smith, Charles L. Beach, Dalia Mahmoud, Laura Weber, Henry J. Henk

Research output: Contribution to journalArticlepeer-review

Abstract

Background: This study examined patient outcomes using real world data for acute myeloid leukemia (AML) patients initiating treatment.Methods: A retrospective, administrative claims-based, comparative analysis was developed to study outcomes for AML patients initiating treatment with decitabine or azacitidine between January 2006 and June 2012.Results: Treatment with azacitidine was associated with a longer median overall survival (10.1 versus 6.9 mos., p = 0.007) and a lower risk of hospitalization (HR 0.787, p = 0.02) compared to treatment with decitabine.Conclusions: This analysis of the outcomes of real-world treatment of AML patients with demethylating agents suggests that azacitidine may result in clinically superior outcomes than decitabine.

Original languageEnglish (US)
Article number10
JournalExperimental Hematology and Oncology
Volume3
Issue number1
DOIs
StatePublished - Mar 25 2014

Keywords

  • Acute myeloid leukemia
  • Azacitidine
  • Decitabine
  • Hospitalization
  • Managed care
  • Real-world
  • Survival

ASJC Scopus subject areas

  • Hematology
  • Oncology
  • Cancer Research

Fingerprint Dive into the research topics of 'Survival and hospitalization among patients with acute myeloid leukemia treated with azacitidine or decitabine in a large managed care population: A real-world, retrospective, claims-based, comparative analysis'. Together they form a unique fingerprint.

Cite this